Ruxotor 10 Mg (Ruxolitinib Phosphate)

Introduction

Ruxotor 10 mg, containing Ruxolitinib Phosphate, is a highly effective oral Janus kinase (JAK1 and JAK2) inhibitor developed for the management of serious hematological and immune-related disorders. Manufactured by Everest Pharmaceuticals Ltd. and supplied globally by Orio Pharma, this medicine provides a modern therapeutic solution for patients diagnosed with myelofibrosis, polycythemia vera (PV), and graft-versus-host disease (GVHD).

By targeting abnormal signaling pathways, Ruxotor helps control disease symptoms, reduce spleen size, and improve overall quality of life in patients suffering from bone marrow disorders and immune complications.

Key Benefits of Ruxotor 10 mg

Reduces spleen size in patients with myelofibrosis.
Improves blood cell counts and helps reduce the need for frequent phlebotomy in polycythemia vera.
Relieves symptoms such as fever, night sweats, weight loss, and bone pain.
Effective in GVHD management, improving survival rates after stem cell transplantation.
Oral administration makes it a convenient option compared to injectable therapies.
Well-researched molecule with proven clinical efficacy across multiple studies.

Indications

Ruxotor 10 mg (Ruxolitinib Phosphate) is indicated for the treatment of:

Intermediate or high-risk myelofibrosis, including primary, post–polycythemia vera, or post–essential thrombocythemia myelofibrosis.
Polycythemia vera (PV) in patients resistant to or intolerant of hydroxyurea.
Steroid-refractory acute and chronic graft-versus-host disease (GVHD) after stem cell or bone marrow transplantation.

Pharmacology and Mechanism of Action

Ruxotor contains Ruxolitinib Phosphate, a potent JAK1/JAK2 inhibitor. The JAK-STAT pathway plays a key role in blood cell production and immune function. In patients with myelofibrosis or polycythemia vera, overactivation of this pathway leads to uncontrolled cell proliferation, abnormal cytokine signaling, and spleen enlargement.

By inhibiting JAK1 and JAK2, Ruxotor helps:

Suppress abnormal cytokine activity.
Restore balance in blood cell production.
Control disease progression.
Provide significant symptom relief.

Dosage and Administration

Starting dose: Typically 5 mg to 20 mg taken orally twice daily, depending on patient’s blood counts and disease condition.
Dose adjustment: Required based on platelet count, hemoglobin levels, and overall patient tolerance.
Administration: Can be taken with or without food. Swallow tablets whole with water.

Side Effects

Like other advanced therapies, Ruxotor may cause side effects. The most common include:

Low blood cell counts (anemia, thrombocytopenia, neutropenia).
Headache and dizziness.
Increased risk of infections.
Bruising and bleeding tendencies.
Fatigue and weight gain.
Elevated liver enzymes.

In rare cases, more serious adverse effects may occur. Regular monitoring of blood counts is essential during therapy.

Contraindications

Ruxotor should not be used in patients with:

Severe liver impairment without proper medical supervision.
Active, untreated infections.
Known hypersensitivity to Ruxolitinib or any tablet component.

Drug Interactions

Ruxotor may interact with other medicines, including:

Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin).
CYP3A4 inducers (e.g., rifampin, carbamazepine).
Anticoagulants and antiplatelet agents (increasing bleeding risk).

Use in Special Populations

Pregnancy: Not recommended; may cause harm to the fetus.
Breastfeeding: Should be avoided; the drug may pass into breast milk.
Pediatric use: Safety and efficacy not established.
Elderly patients: May require dose adjustment due to increased risk of side effects.

Overdose Management

In case of overdose, patients may experience severe low blood counts or infection risk. Immediate medical attention and supportive care are required.

Storage Instructions

Store below 30°C (86°F) in a dry place.
Keep away from direct sunlight and moisture.
Keep out of reach of children.

Manufacturer – Everest Pharmaceuticals Ltd.

Everest Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer with a strong reputation for producing high-quality generic and specialty medicines. The company ensures compliance with international manufacturing standards, making its oncology and hematology products trusted worldwide.

Supplier – Orio Pharma

Orio Pharma is a reliable global supplier of oncology and hematology medicines, ensuring timely access to critical treatments like Ruxotor 10 mg. With a commitment to quality and affordability, Orio Pharma works with healthcare providers, hospitals, and distributors to deliver advanced therapeutic solutions to patients worldwide.

Conclusion

Ruxotor 10 mg (Ruxolitinib Phosphate) is an advanced JAK inhibitor that brings hope to patients with serious blood disorders like myelofibrosis, polycythemia vera, and GVHD. Manufactured by Everest Pharmaceuticals Ltd. and supplied by Orio Pharma, it stands as a trusted therapy backed by clinical research and patient outcomes.

If you are a healthcare provider, distributor, or patient looking for Ruxotor 10 mg, Orio Pharma ensures a reliable and professional supply of this life-saving medication.